HEALTH

  • 563
  • 536

Alzheimer's drug Leqembi falls short of blockbuster status in faltering US rollout - Financial Times

High costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval

image

Ads

Video News

Hot News

Ads

News Letter

Your email address will not be this published. Required fields are News Today.